Positive Contrast MRI of Magnetically Labeled Human Cervical Carcinoma Cells and Tumor Monitoring

Y. Kim1, K. Bae2, S-S. Yoo3, T. Park2, and H. Park1

1Electrical Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea, Republic of; 2Biological Science, Korea Advanced Institute of Science and Technology, Daejeon, Korea, Republic of; 3Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States

Introduction: There are rapidly increasing interests in cellular and molecular magnetic resonance imaging (MRI) techniques using contrast agents for the visualization of the migration, and growth of various types of cells, including stem cells and tumor cells. Several MR contrast agents have been suggested for use in cellular MRI. Among them, superparamagnetic iron oxide (SPIO)-based contrast agents are currently being evaluated as potential markers for the monitoring of cellular growth, migration, or proliferation since SPIO’s can remain internalized for more than several weeks [1]. As a result the technique is applicable to monitoring tumor growth. However, SPIO-loaded cells cause signal reduction (negative contrast) associated with spin dephasing. This negative-contrast visualization is sometimes problematic since it can be confused with the signal voids caused by tissue inhomogeneity (low intensity). Several researchers have proposed positive-contrast imaging (PCI) methods using either spectral selection of an off-resonance region near the labeled cells [2, 3], suppression of non-labeled regions by dephasing [4] or spectral selection using different echo times [5]. We were motivated to investigate a method to generate positive-contrast by using a susceptibility weighted echo-time encoding technique (SWEET) [6]. We demonstrate the SWEET method can be useful to detect the magnetically labeled human cervical carcinoma (KB) cells implanted in mice, and to monitor tumor growth in vivo for a duration of 2 weeks.

Methods: We verified the SWEET method as a PCI approach from in vitro gelatin gel phantom and animal (mouse) imaging. Furthermore, we monitored the tumor growth from injected cancer cells for 2 weeks and confirmed this growth with histological sections. Cell preparation: Human cervix carcinoma (KB) cells were used for tumor monitoring and cell morphology evaluation. A combination of a SPIO (Feridex, Berlex laboratories Inc) and a PLL (Poly-L-lysine) was used for efficient cell transfection. KB cells (20,000 cells/cm²) were obtained from a conventional spin-echo sequence and the SWEET method with an echo-time shift (Imaging parameters: TR/TE=500/20 ms, 256 x 256 matrix, 10 x 10 cm² FOV, slice thickness=3 mm). An echo-time encoding step (dT) in in vitro phantom imaging: In order to verify the feasibility of the SWEET method, gelatin phantoms were constructed using 35 mm diameter vials. Phantoms containing eight different concentrations of cells (1x10⁶, 5x10⁵, 2x10⁵, 1x10⁵, 5x10⁴, 1x10⁴, 5x10³ labeled, and 5x10⁵ unlabeled KB cells) were prepared to image various concentrations of SPIO-labeled cells within a fixed area (selected data shown Fig. C to E). All MR images were acquired on a 3.0T MRI scanner (ISOL Tech, Korea) with a customized animal coil. Positive-contrast images were obtained from a conventional spin-echo sequence and the SWEET method with an echo-time shift (Imaging parameters: TR/TE=500/40ms; shifted echo-time=22ms; 256x256 matrices; 8x8 cm² Field-of-View (FOV); 1.5mm slice thickness with no gap; 2 number of excitations; NEX). In vivo mouse imaging: For the examination of the efficacy of our method as an animal model as well as the monitoring of the proliferation of SPIO-labeled cancer cells, we performed an in vivo animal study using nude mice. Either SPIO-labeled or unlabeled KB cells were harvested and then resuspended in PBS with a concentration of 3x10⁷ cells/mL. One hundred microliter aliquots of the cell suspension were injected at two different sites; (1) subcutaneously onto the dorsal side and (2) intramuscularly into the hind legs of a BALB/c nude mouse (n=3). The left side was injected with SPIO-labeled KB cells implanted and the right side with unlabeled KB cells acting as a control. For all mice, MR images were acquired prior to injection of the cells and at 8 subsequent time points (day 0; 1 hour after injection, day 1, day 2, day 4, day 7, day 9, day 12, day 14) after injection in order to monitor the proliferation of the cancer cells as well as tumor growth. The timing parameters were: TR/TE=500/20 ms, 256 x 256 matrix, 10 x 10 cm² FOV, slice thickness=3 mm. An echo-time encoding step (dT) in SWEET imaging used 4.48 ms and a total acquisition time was 4 min with 2 NEX.

Results: The effective internalization of SPIO particles was observed from fluorescent and the microscopic images as shown in Figures (A) and (B), respectively. The SWEET method selectively enhanced the effect of the field inhomogeneity caused by SPIO-labeled KB cells from the gelatin phantom (Fig. G through E) and mouse (Fig. F) imaging. Figure (C) shows the image from a conventional spin-echo sequence and (D) illustrates the susceptibility effect due to the SPIO-labeled KB cells by the SWEET method on the same sample. In Figure (E), a positive contrast image was generated from the difference between (C) and (D) (note that effective removal of the background signals is evident). Figure (F) shows the in vivo mouse MRI results (see figure caption for more information). Labeled cells were marked in red arrows and unlabeled control cells in white arrows. Through the longitudinal MRI of the implanted tumor over a 2 week period, a solid tumor mass was observed to have grown from the cancer cells at a subcutaneous flank (panels on upper row) and intra-muscular space (bottom row) in Figure (G); After 2-weeks of MR imaging, we assessed histology sectioning in order to verify the correlation between positive-contrast in MR images and the existence of SPIO particles (data not shown).

Discussion: We have demonstrated that a proposed SWEET scheme has enabled in vitro and in vivo positive-contrast visualization without the use of complicated pulse sequence programming. However, a fundamental limitation of the proposed method is that susceptibility artifacts originate from sources other than labeled cells, such as the air-tissue interface of organs or the body, as seen elsewhere [2]. Additionally, the positive-contrast is shown as an enhancement around the edge of SPIO-labeled tumor sites as the tumor mass enlarges (in Figure G: Day 14). Recently, the simultaneous use of fluorinated nano-contrast agents ¹F and ¹H MR imaging has been validated on clinical MR scanners [7, 8]. The optimization of the SWEET technique and integration with the novel contrast agents constitutes further direction of our future investigation.